Sinovac Biotech
Post in 2018
Sinovac Biotech Ltd. is a biopharmaceutical company based in Beijing, China, specializing in the research, development, manufacturing, and commercialization of vaccines for human infectious diseases. Its product portfolio includes vaccines for hepatitis A and B, seasonal influenza, H5N1 and H1N1 pandemic influenza, mumps, and enterovirus 71, which causes hand, foot, and mouth disease. Notable marketed products include Healive, an inactivated hepatitis A vaccine, and Panflu.1, a vaccine for H1N1 influenza, which was the first of its kind approved globally. Sinovac is also recognized as a key supplier of the H5N1 influenza vaccine for government stockpiling in China. The company is actively developing new vaccines, including those for pneumococcal diseases and rubella, with several in various stages of clinical trials. Sinovac collaborates with prominent institutions such as Peking University and the Chinese Academy of Medical Sciences, and it exports selected vaccines to countries like Mongolia, Nepal, and the Philippines. Founded in 1999, Sinovac plays a significant role in addressing public health needs in China and beyond.